PD-1/L1抑制剂在头颈部鳞状细胞癌治疗中的应用进展

The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma

头颈部鳞状细胞癌(head and neck squamous carcinoma,HNSCC)是全球最常见的癌症之一,年死亡人数超过350000例,5年总生存率仅40%~50%[1]。最新NCCN及CSCO指南指出,复发/转移性HNSCC(relapse/metastatic HNSCC,R/M HNSCC)患者可接受一线EXTREME/CHANGE-Ⅱ方案。

Over the past few years,the FDA has approved PD-1/L1 inhibitor for the treatment of advanced head and neck squamous cell carcinoma,involving PD-1/L1 inhibitor monotherapy,PD-1/L1 inhibitor combined with chemoradiotherapy,combined with targeted therapy,combined with neoadjuvant immunotherapy and duplex-block of immune checkpoints and so on.Herein,we briefly review the latest research results in this field,and summarize the application and efficacy of immunotherapy in the treatment of head and neck squamous cell carcinoma,which will benefits such patients to develop more precise and individualized treatment plans.